Routine care data and the benefits of GLP1 receptor agonists on slowing kidney function decline

Affiliations

¹ Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: xuyang_pucri@bjmu.edu.cn.
² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Epidemiology, Centre for Epidemiology and Population Health, Paris-Saclay University, Paris, France.
³ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁴ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.

Comment

Yang Xu et al. Kidney Int. 2023 Sep.

. 2023 Sep;104(3):618-619.

doi: 10.1016/j.kint.2023.06.009.

¹ Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: xuyang_pucri@bjmu.edu.cn.
² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Epidemiology, Centre for Epidemiology and Population Health, Paris-Saclay University, Paris, France.
³ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁴ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.

No abstract available

Comment in

The authors reply.
Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Mosenzon O, Rasmussen S, Bain SC. Tuttle KR, et al. Kidney Int. 2023 Sep;104(3):619. doi: 10.1016/j.kint.2023.06.008. Kidney Int. 2023. PMID: 37599024 No abstract available.

Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, Rasmussen S, Bain SC. Tuttle KR, et al. Kidney Int. 2023 Apr;103(4):772-781. doi: 10.1016/j.kint.2022.12.028. Epub 2023 Feb 2. Kidney Int. 2023. PMID: 36738891